Novel targeted agents in Her-2 positive and triple negative breast cancer by Tryfonopoulos, Dimitrios
 Novel targeted agents in Her-2 
positive and triple negative breast 
cancer 
 
A thesis submitted for the degree of M Sc 
 By Dimitrios Tryfonopoulos, MD 
 
 
The work in this thesis was performed under the supervision of 
Dr Norma O’Donovan and Prof John Crown 
 
 
National Institute of Cellular Biotechnology 
School of Biotechnology 
Dublin City University 
 
 
 
 
 
 
  
 
 
I hereby certify that this material, 
programme of study leading to the award of MSc is entirely my own work, and 
that I have exercised reasonable care to ensure that the work is original, and 
does not to the best of my knowledge breach any law of copyr
been taken from the work of others save and to the extent that such work has 
been cited and acknowledged within the text of my work.
 
 
 
Signed: ____________  ID No.: _
1 
which I now submit for assessment on the 
 
59114959_ Date: 
ight, and has not 
15/5/2013
2 
 
 
Contents 
I. Abstract ....................................................................................................................... 4 
II. List of common abbreviations .................................................................................... 5 
Chapter  1. Literature Review ............................................................................................ 6 
1.1 Introduction ............................................................................................................ 7 
1.2 Targeted therapies and breast cancer ........................................................................ 7 
1.3 Molecular classification of breast cancer .................................................................... 8 
1.3.1 ER negative, PR negative, Her-2 normal (triple negative) breast cancer .............. 9 
1.3.1.1 Possible targets for triple negative breast cancer ..................................... 10 
1.3.2 Her-2/neu amplified/overexpressed breast cancer ............................................ 16 
1.3.2.1 Targeted therapy for Her-2 positive breast cancer ................................... 17 
1.3.3 Luminal breast cancer ......................................................................................... 19 
1.3.3.1 Targeted treatments for luminal-type breast cancer commonly used in 
clinical practice. ........................................................................................................ 20 
1.4 Resistance to currently used targeted therapies .................................................. 21 
1.5 Study Objectives .................................................................................................... 22 
Chapter 2. Materials and Methods .................................................................................. 24 
2.1 Cell lines, cell culture and reagents ............................................................. 25 
 
2.2 Proliferation assays ........................................................................................ 27 
2.3 Combination assays and synergy analysis ......................................................... 28 
2.4 Preparation of cell lysates ............................................................................. 28 
2.5 Immunoblotting analysis ................................................................................ 28 
2.6 In vivo testing ................................................................................................... 29 
2.7 Statistical considerations ............................................................................... 30 
Chapter 3. Evaluation of multi-target kinase inhibitors in breast cancer cell lines ......... 32 
3.1 Introduction ................................................................................................... 33 
3.2 Sensitivity to multi-target kinase inhibitors ....................................................... 33 
3 
 
3.3 Cell signalling inhibitors in triple negative breast cancer cell lines .................... 35 
3.4 Summary ............................................................................................................. 37 
Chapter 4. Preclinical evaluation of dasatinib in triple negative breast cancer cell lines38 
4.1 Introduction ........................................................................................................ 39 
4.2 In vitro evaluation of dasatinib in combination with chemotherapy ................. 39 
4.3 Biomarkers of dasatinib response ...................................................................... 45 
4.4 In vivo testing of dasatinib plus chemotherapy in triple negative breast 
cancer 48 
4.5 Summary ............................................................................................................. 50 
Chapter 5. Evaluation of combinations of sunitinib with current therapies for HER2 
positive and triple negative breast cancer ....................................................................... 51 
5.1 Introduction ................................................................................................... 52 
5.2 Sunitinib plus trastuzumab in HER-2 positive breast cancer cell lines .......... 52 
5.4 Summary ............................................................................................................. 57 
Chapter 6. Discussion ....................................................................................................... 58 
6.1 Discussion ...................................................................................................... 59 
6.2 Her-2 amplified cell lines ............................................................................... 59 
6.3 Triple negative cell lines ................................................................................ 60 
6.4 Conclusions ......................................................................................................... 63 
References ........................................................................................................................ 65 
DISSEMINATION OF RESULTS ....................................................................................... 76 
FUNDING ...................................................................................................................... 76 
 
  
4 
 
I. Abstract 
Novel targeted agents in Her-2 positive and triple negative breast cancer  
Dr DimitriosTryfonopoulos 
 
The development of Her-2 targeted therapies has improved the prognosis for 
patients with Her-2 positive breast cancer. However, not all Her-2 positive 
tumours respond to treatment with Her-2 antagonists. Triple negative cancers 
are resistant to hormone and Her-2 targeted therapies. This project focused on 
improving response in Her-2 overexpressing breast cancer and on developing 
effective targeted therapy strategies for triple negative breast cancer. 
We tested a number of multi-target kinase inhibitors (imatinib, sunitinib, 
pazopanib and dasatinib) in Her-2 positive and triple negative breast cancer cell 
lines, alone and in combination with other agents.  
Two of the Her-2 positive cell lines showed moderate sensitivity to sunitinib 
malate. Combined treatment with sunitinib and trastuzumab showed improved 
response compared to either drug alone, in the four Her-2 positive cell lines 
tested. 
Dasatinib inhibited growth in 3 of the 5 triple negative but in only 1 of the 4 Her-2 
positive cell lines tested. Based on response to the other multi-target kinase 
inhibitors, which have overlapping target specificities, and the Src,PP2, our 
results suggest that sensitivity to dasatinib in triple negative breast cancer is due 
to inhibition of ephrin type A receptors. Consistent with this hypothesis, neither 
Src expression nor phosphorylation predicted sensitivity to dasatinib, but high 
levels of Ephrin type A receptor 2 protein correlated with dasatinib sensitivity. 
High levels of caveolin 1 and caveolin 2 also correlated with dasatinib sensitivity 
in the panel of cell lines. 
Dasatinib combined with cisplatin was synergistic in the three dasatinib-sensitive 
cell lines. Dasatinib, in combination with 5’-deoxy-5’-fluoruridine, displayed 
synergy or additivity. Moderate synergy was observed with docetaxel in two 
triple negative cell lines.  
In conclusion, we have identified dasatinib with cisplatin as a rational 
combination for testing in triple-negative breast cancer, and have identified a 
panel of putative predictive biomarkers for dasatinib sensitivity (EphA2, CAV1 
and CAV2). 
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II. List of common abbreviations 
 
5’-DFUR: 5’-Deoxy-5’Fluorouridine 
BRCA: Breast-ovarian Cancer 
CI: Combination Index 
EGFR: Epidermal Growth Factor Receptor 
EphA receptor: Ephrin type A receptor 
ER: Estrogen Receptor 
HER-2: Human Epidermal growth factor Receptor -2 
mTOR: mammalian Target of Rapamycin 
PARP: Poly-ADP-Ribose Polymerase 
PDGF: Platelet-Derived Growth Factor 
PFS: Progression-Free Survival 
PR: Progesterone Receptor 
VEGF: Vascular Endothelial Growth Factor 
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1.1 Introduction 
 
Breast cancer is the most common form of non-skin cancer in women and the 
5th cause of cancer death. Breast cancer is a remarkably heterogeneous 
disease characterized by aberrant signal transduction. During the last 20 years 
translational research has focused on isolating and interfering with signals 
responsible for breast cancer pathogenesis and progression. Some of these 
molecular drivers of carcinogenesis, like the estrogen receptor and the human 
epidermal growth factor receptor-2 (Her-2) pathways have been partially 
elucidated and targeted. However, many more still need to be defined.  
These advances have shifted breast cancer classification from pathologic to 
molecular, allowing for more accurate prognostic and predictive information and 
rational drug development.  The proof of principle for this approach was the 
discovery of Her-2 receptor and the development of trastuzumab. 
 
1.2 Targeted therapies and breast cancer 
 
          Breast cancer was the first solid tumour where targeted therapy was 
applied. The discovery of estrogens and estrogen receptor signalling led to the 
development of hormone manipulation treatment which radically changed the 
survival and quality of life for women with hormone-sensitive breast cancer. 
Further molecular pathways involved in cancer growth and progression have 
been elucidated and moleculary targeted agents are being developed to block 
these signalling pathways. Targeted therapies tend to be less toxic compared to 
chemotherapy due to their selectivity and are often more effective, as in the 
case for trastuzumab in Her-2 positive breast cancer (1). Targeted therapies can 
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be broadly divided into 2 categories: monoclonal antibodies that block receptors 
or ligands extracellularly and small molecules which either inhibit intracellular 
protein kinases or other pathways relevant to cellular proliferation, growth and 
metastatic potential. The effectiveness of targeted therapies relies on the 
importance and uniqueness of the selected molecular pathway for tumour 
development and progression. Therefore, and since solid tumours including 
breast tumours are heterogenous, target selection is of paramount importance.  
1.3 Molecular classification of breast cancer 
 
Gene expression profiles have classified breast cancer into biologically and 
clinically meaningful subgroups (2) (3). These intrinsic subtypes consist of 
luminal, normal-like, HER-2 amplified, basal-like and most recently claudin-low 
tumours. Even within this classification important heterogeneity in clinical 
outcome exists. 
In practice, since genomic methods of tumour classification are often not readily 
available, the use of simple immunohistochemical markers have proven useful 
but not perfect surrogates of the molecular subgroups which serve as prognostic 
and predictive markers for clinical use and clinical trial design (Table 1.1). 
Table 1.1.Immunohistochemical subtypes of breast cancer (4). 
Subtype Phenotype 
Luminal A ER/PR +, HER-2 -, Ki-67<15-20% 
Luminal B ER/PR +, Ki-67>15-20% 
Her-2 
overexpressing 
ER-, PR-, HER-2 + 
Triple negative ER-, PR-, HER-2 - 
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1.3.1 ER negative, PR negative, Her-2 normal (triple negative) breast 
cancer 
Breast cancers that do not overexpress estogen receptors, progesterone 
receptors or Her-2 (triple negative) are an immunohistochemical surrogate of 
basal-like breast cancer. However, there is not a complete overlap between 
triple negative and basal-like tumours. Approximately 50-75% of triple negative 
tumours are basal-like, expressing the basal cytokeratins 5, 6 or 17. These 
tumours are highly proliferative, p53 and RB1-protein deficient and often BRCA1 
mutated (5). As gene expression studies evolve, further sub-classification is 
underway (3). 
In general, triple negative breast cancers often share clinicopathologic 
characteristics. They are usually associated with a younger age, a high mitotic 
index and an adverse prognosis (6). Several studies have demonstrated 
chemosensitivity in this kind of tumour, especially the basal-like, yet the patients 
who relapse or whose disease progresses have a dismal prognosis and a short 
survival (triple negative paradox) (7) (8) (9). Although it represents the minority 
(10-25%depending on the demographics of the population) of breast cancer 
subtypes, due to its poor prognosis it accounts for a disproportionate number of 
breast cancer deaths.  
The triple negativity results in a lack of targeted treatment opportunities. We 
therefore possess no “druggable” nuclear or surface receptor and in search of 
potential targets, sub-classification according to distinct characteristics should 
be helpful. Several studies have pointed out possible subgroups of triple 
negative tumours, including the HER-2 enriched, basal and claudin-low (3) 
(5).The HER-2 enriched gene expression subtype is a minor constituent of the 
triple negative group. These tumours are phenotypically triple negative despite 
having the HER-2-enriched gene expression signatures. Additionally, further 
classification is underway using the integrity of BRCA repair pathway (BRCA 
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mutations or BRCAness). These efforts have produced possible clinically 
relevant targets which are summarised in table 1.2. 
 
Table 1.2 Current treatment strategies for targeting triple negative breast cancer 
in clinical trials. 
Target Drugs 
EGFR Cetuximab, erlotinib (10) (11) 
VEGF(R) Bevacizumab, ramucirumab, sorafenib, cediranib, apatinib 
(12) 
DNA Platinum and alkylators,  PARP inhibitors (13) (14) 
mTOR Temsirolimus, everolimus 
SRC Dasatinib (15) 
 
 
1.3.1.1 Possible targets for triple negative breast cancer 
(i) Epidermal growth factor receptor (EGFR) 
Epidermal growth factor receptor expression has been observed in 54% of basal 
breast cancer cell lines and has been independently associated with poor 
outcome (16) (17). In addition, EGFR mRNA has been detected more frequently 
and at higher levels in breast cancer tumour samples of basal subtype (4). 
Preclinical studies  also showed EGFR overexpression in triple negative as 
compared to Her-2 positive cell lines. In the same study sensitivity to the small 
molecule EGFR inhibitor was tested. Although single agent EGFR inhibitor was 
ineffective, gefitinib enhanced sensitivity to taxane and platinum chemotherapy 
in the triple negative cell lines (18). Preliminary results of the BALI-1 clinical 
study suggested better response rates and progression free survival in patients 
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with metastatic triple negative breast cancer when EGFR targeting monoclonal 
antibody cetuximab was added to cisplatin chemotherapy (10) . 
(ii) BRCA 1 
Women who carry mutations in the BRCA-1 gene develop breast cancer which 
is often basal-like. There has been an increased interest in this subgroup, since 
it shares common characteristics with sporadic basal-like cancers, such as the 
triple negative phenotype, high grade, pushing margins, EGFR expression, high 
p53 mutation rate, X-chromosome inactivation pattern and sensitivity to DNA 
damage (19) (20). The BRCA 1 gene plays an important role in mediating the 
DNA damage response. As a result, BRCA-1-deficient tumours are particularly 
sensitive to DNA damaging agents, such as alkylators, platinum salts and 
radiation treatment. Unfortunately, in clinical practice we are still lacking clinical 
study data supporting the use of BRCA-1 pathway as an effective target for triple 
negative breast cancer. 
(iii) Poly-ADP-ribose polymerase (PARP) 
PARP may be another therapeutically meaningful target in patients with triple 
negative breast cancer. In the case of DNA damage, apart from BRCA-1 repair 
(homologous recombination), PARP-mediated base excision repair is a key 
mechanism. Inhibition of PARP in BRCA-1 deficient cells deprives cells of two 
vital repair mechanisms and leads to cell death (synthetic lethality) (21) (22).  
Conveniently, the non-cancer cells of BRCA-1 mutation carriers retain one 
functional allele of the BRCA-1 gene and can still repair DNA damage. 
Therefore, PARP inhibition is selective for cancer cells and generally has no 
toxicity to healthy cells. Additionally, inhibition of PARP can be better exploited 
in BRCA-1 mutation carriers due to synthetic lethality. 
Results of two relevant clinical trials are available. Olaparib, a potent PARP 
inhibitor was used as a single agent in pretreated BRCA-1 or -2 mutation 
carriers with breast cancer. Remarkably there was a 41% response rate and a 
median PFS of 5.7 (4.6-7.4) months (23).  On the other hand results of a phase 
III study using a weaker PARP inhibitor, iniparib, along with carboplatin and 
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gemcitabine chemotherapy in unselected triple negative metastatic breast 
cancer patients, were negative, although phase I and II results were very 
promising (24; 14). 
(iv) Angiogenesis 
Anti-angiogenic treatment, with the monoclonal antibody bevacizumab, has 
been tested extensively in unselected patients with metastatic breast cancer. It 
has produced positive results in terms of prolonging progression free survival 
but has failed to show an overall survival benefit. Subset analyses suggested 
that patients with triple negative breast cancer benefited as much as, if not more 
than, the average (12). Ongoing studies will provide data on effectiveness in 
triple negative breast cancer.  
The small molecule antiangiogenic agent, sunitinib, which targets PDGFR-a and 
–b, VEGFR-1, -2, -3, c-KIT, FLT-3, CSF-1R and RET, has also been tested in 
clinical studies of unselected metastatic breast cancer patients, in combination 
with chemotherapy. Unfortunately, studies were prematurely interrupted due to 
lack of efficacy and toxicity.  
(v) C-KIT 
The growth factor receptor, c-KIT, is expressed in 30% of basal-like cancers 
(16). Inhibitors of c-KIT have shown modest activity in patients with metastatic 
breast cancer, yet there are no results to date in a c-KIT-mutated subpopulation 
and therefore the validity of c-KIT as a molecular target remains undetermined 
(25). 
(vi) SRC 
The SRC family kinases are non-receptor protein tyrosine kinases that have 
been extensively studied in cancer. Src is a protooncogene which appears to be 
a key messenger in important cellular pathways, including proliferation, 
differentiation, survival, motility and angiogenesis (26) (27). It can be activated 
either through ligand activation of cell surface receptors (e.g. EGFR) or by 
cytoplasmic proteins (e.g.focal adhesion kinase FAK, Crk-associated substrate 
CAS) or by dephosphorylation of tyrosine residue Y530 (28) (29). Activation of 
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SRC leads to an open conformation of the SRC protein and further downstream 
signalling as illustrated in figure 1.1. Increased EGFR, HER-2, PDGFR, VEGFR, 
ephrin, FAK signalling lead to elevated SRC activity (30) (31) (32). Preclinical 
studies have implicated SRC inhibition as a therapeutic option for triple negative 
breast cancer (33) (30) (34). Dasatinib, an orally active small molecule inhibitor 
of SRC-family and Abl kinases is approved for treating Philadelphia 
chromosome-positive leukemias. Additionally, dasatinib has been shown to 
inhibit invasion, growth and metastasis of breast cancer cell lines and 
particularly of basal-type. Among 39 human breast cancer cell lines tested, 
basal-type cell lines as well as cell lines that have undergone epithelial-to-
mesenchymal transition (post-EMT) were highly sensitive to dasatinib. 
Additionally, a highly significant relationship between basal-type and post-EMT 
breast cancer cell lines and sensitivity to dasatinib was observed (33). Xenograft 
studies of dasatinib in athymicmice which were inoculated with the triple 
negative breast cancer cell lineMDA-MB-231 demonstrated antitumour activity 
(34). Results of a phase II clinical study of single agent dasatinib in unselected 
triple negative breast cancer patients showed limited activity but acceptable 
toxicity profile (15).  
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Figure 1.1.Basal conformation, mechanisms of activation and active 
conformation of SRC kinase (35). 
 
(vii) PI3K-AKT-mTOR 
Mammalian Target of Rapamycin (mTOR) is a downstream member of the 
phosphatidoinositide 3-kinases (PI3-K)/AKT kinase signalling pathway which 
can regulate cancer cell growth and cell cycle progression in malignant cells 
(36). mTOR, is a cell-signaling protein that regulates the response of tumour 
cells to nutrients and growth factors, as well as controlling tumour blood supply 
through effects on Vascular Endothelial Growth Factor, VEGF. The PI3K/Akt 
pathway is thought to be over activated in numerous cancer types. Over-
activation of the PI3K/Akt kinase pathway is frequently associated with 
mutations in the phosphatase and tensin homologue (PTEN) gene, which is the 
second commonest mutation of a tumour suppressor gene. In preclinical and 
clinical studies chemotherapy and hormone therapy have proven to be more 
effective in the presence of a PI3-K/AKT/mTOR pathway inhibitor. Combined 
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treatment with an mTOR inhibitor and hormone treatment produced promising 
results in a phase 3 randomized study (37). Inhibition of this pathway in triple 
negative breast cancer is still under clinical investigation. Several phase I and II 
studies with combinations of everolimus or temsirolimus and other targeted 
agents (lapatinib, neratinib,etc) or chemotherapy (paclitaxel, carboplatin, etc) in 
triple negative breast cancer are ongoing. 
(viii) MAPK 
The mitogen-activated kinase (MAPK) pathways are major signal transduction 
routes that transfer and amplify messages from the cell surface to the nucleus. 
MAPK signaling pathways modulate many cellular events including: mitogen-
induced cell cycle progression through the G1 phase, regulation of embryonic 
development, cell movement and apoptosis, as well as cell differentiation (38). 
These pathways are organized in 3 kinase modules consisting of a MAP kinase, 
an activator of MAP kinase (MAP Kinase Kinase or MEK) and a MAP Kinase 
Kinase Kinase (MEK Kinase, MEKK, or MAPK Kinase Kinase). The Ras-Raf-
MEK-ERK pathway has been implicated in uncontrolled cell proliferation and 
survival. This pathway is activated by a range of growth factor receptors, 
including epidermal growth factor receptor, platelet-derived growth factor 
receptor, type-1 insulin-like growth factor receptor, and fibroblast growth factor 
receptors.  The pathway can also be activated by cytokines, steroid hormones, 
and several agonists that act via G-protein-coupled receptors. Growth factor 
stimulation leads to a signal transduction cascade, which involves sequential 
activation of a number of cytoplasmic and nuclear targets. MEK1/2 is a dual-
specific kinase that is essential to the Ras-Raf-MEK-ERK pathway.  All three Raf 
isoforms share Ras as a common upstream activator, whereas MEK is the only 
commonly accepted downstream substrate.MEK1/2 serves to amplify signals to 
ERK1/2 (also known as MAPK1/2) through phosphorylation of key tyrosine and 
threonine residues, thereby activating its catalytic activity. Activation of ERK1/2 
via MEK1/2 is a critical step in growth factor signaling, as active ERK mediates a 
range of cellular effects including cell proliferation, migration and differentiation 
as well as promotion of epithelial to mesenchymal transition (39). This pathway 
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has been implicated with resistance to chemotherapy and adverse prognosis in 
patients with triple negative breast cancer (40) (41). Since there is often co-
activation of the MAPK and AKT pathways, several phase I clinical trials are 
currently exploring the activity of dual inhibitors in patients with triple negative 
breast cancer (42). 
 
1.3.2 Her-2/neu amplified/overexpressed breast cancer 
The Her-2 amplified /overexpressed and ER/PR negative phenotype is a 
subgroup of breast cancer associated with a poor prognosis in the absence of 
Her-2 targeting treatment.  
The Her system consists of several ligands including EGF, TGF, amphiregulin, 
neuregulins, etc and 4 receptor tyrosine kinases: EGFR, Her-2, Her-3 and Her-4 
(43) (44). Activation and downstream signalling result in cell proliferation, 
differentiation, survival and gene transcription. Her-2/neu (cErb-B2) is a 
protooncogene which is located on chromosome 17q12. Her-2 possesses no 
known ligand. EGFR, Her-2 and Her-4 have an active kinase domain, whereas 
the Her-3 intracellular kinase domain is inactive. In response to ligand binding, 
receptors form homo- or heterodimers, their cytoplasmic tyrosine kinase is 
phosphorylated and numerous downstream signals are generated. Her-2 and 
Her-3 signals appear to be most potent (45). The best studied signalling 
pathways induced by the HER pathway are the phosphatidoinositol-3 kinase-
Akt-mTOR pathway, the Ras-mitogen-activated protein kinase (Ras-MAPK) and 
the phospholipase Cγ-protein kinase C pathway (46).  
Her-2 overexpression is usually due to gene amplification and results in an 
increased number of Her-2 molecules on the cell surface of cancer cells. This 
occurs in 15-30% of breast cancers and is of prognostic and predictive 
significance. Since 1987, several studies have correlated Her-2 amplification 
with shorter time to relapse, poorer overall survival and higher incidence of 
adverse histologic features, such as lymph node involvement, lymphovascular 
invasion and brain metastases (47). Overexpression of Her-2 has been shown 
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predictive of response to anthracyclines, resistance to hormonal treatment and 
response to anti-Her-2 treatment, including trastuzumab and lapatinib (48) (49) 
(50) (51) (52) (53).  
 
1.3.2.1 Targeted therapy for Her-2 positive breast cancer 
 
1.3.2.1.1 Monoclonal antibodies 
Trastuzumab 
Trastuzumab was the first humanized monoclonal antibody approved for breast 
cancer treatment. It binds to the extracellular domain of Her-2 preventing 
downstream signalling. The exact mechanism of action is still not fully 
elucidated. Several overlapping models have been proposed, including 
downregulation of Her-2, reduction of Her-2 signalling, inhibition of shedding of 
the Her-2 extracellular domain, induction of cell cycle arrest, induction of 
apoptosis, inhibition of angiogenesis and DNA repair and antibody-dependant 
cell-mediated cytotoxicity (ADCC) (46) (54).  
In clinical trials, trastuzumab achieved response rates up to 15% as a single 
agent in pretreated patients with metastatic Her-2 positive breast cancer and 26-
34 % in first line treatment (55) (56). In combination with chemotherapy it nearly 
doubled response rates, prolonged response duration and overall survival and 
reduced risk of death by 20%, compared to chemotherapy alone (1). Several 
studies support trastuzumab use even beyond disease progression and finally 
neoadjuvant and adjuvant trastuzumab for 1 year have been standard of care 
since 2006 in patients with early stage Her-2 positive breast cancer (57) (58).   
Trastuzumab can be safely used concurrently with several chemotherapy agents 
but due to increased risk of cardiomyopathy, concurrent use with anthracyclines 
is not recommended (1).  
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Pertuzumab 
Pertuzumab is a novel humanized monoclonal antibody which is currently 
studied in clinical trials. Unlike trastuzumab, pertuzumab binds to the 
dimerization domain of the Her-2 receptor and inhibits dimerization with other 
HER family receptors (59). Early phase II as well as phase III trial results 
suggest encouraging activity, in combination with trastuzumab and regulatory 
authority approval of this agent is awaited (60) (61). 
T-DM1 
This is a unique antibody-drug conjugate including trastuzumab, a linker and a 
potent cytotoxic agent, DM 1, which is a maytansine analog.  The antibody binds 
to the Her-2 receptor, the receptor along with the T-DM1is internalised and the 
microtubule polymerization inhibitor is released in the cancer cell. A phase II 
study using this conjugate in heavily pretreated Her-2 positive metastatic breast 
cancer patients, resistant to other Her-2 targeting agents showed response rates 
of 32-35%, nearly double of those initially presented with trastuzumab (62). 
Early results of another randomized phase II study comparing T-DM 1 to 
combination docetaxel and trastuzumab showed similar response rates (63). 
Results of the phase III EMILIA study comparing T-DM 1 to the standard 
second-line combination lapatinib-capecitabine in patients with metastatic HER-
2 positive breast cancer progressing after trastuzumab, demonstrated improved 
progression-free survival in patients receiving the antibody-drug conjugate (64).  
 
1.3.2.1.2 Small moleculekinase inhibitors 
Lapatinib 
Lapatinib is a quinazoline, a dual inhibitor of the phosphorylation of the tyrosine 
kinases of Her-2 and EGFR. It has produced activity in trastuzumab pretreated 
metastatic breast cancer patients as a single agent (65). In addition, the 
combination with capecitabine prolonged time to disease progression as 
compared to capecitabine alone (66). Recent phase III trial results confirm 
preclinical data supporting synergistic activity with trastuzumab (67).  
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As with most of the small molecule inhibitors lapatinib is orally administered and 
is generally well tolerated. The most frequent adverse events include diarrhea, 
skin rash and liver function test abnormalities.  
Neratinib 
Neratinib is a next generation orally available, 6,7-disubstituted-4-
anilinoquinoline-3-carbonitrile inhibitor of the HER-2 receptor tyrosine kinase 
with potential antineoplastic activity. Neratinib binds to the HER-2 receptor 
irreversibly, thereby reducing autophosphorylation in cells, apparently by 
targeting a cysteine residue in the ATP-binding pocket of the receptor. 
Treatment of cells with this agent results in inhibition of downstream signal 
transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 
1/DNA synthesis)-phase transition of the cell division cycle; and ultimately 
decreased cellular proliferation. Neratinib also inhibits the epidermal growth 
factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells. 
Neratinib provides greater inhibition of HER2 signaling activity but does not 
increase HER2 protein levels as has been observed with lapatinib (68). Early 
results of several ongoing phase II have reported mixed results.  Final results 
are awaited. 
Other inhibitors 
Heat shock protein 90 (Hsp90) has a role in maintaining Her-2 stability and 
regulates its function. Interaction of Hsp90 and the kinase domain of Her-2 is 
necessary for Her-2 dimerization and activation (69). Preclinical data with 
inhibitors of Hsp90 have shown activity (70).  Other inhibitors affecting Her-2 
protein are under development, including deacetylase inhibitors, vaccine 
immunotherapy etc (71). 
 
1.3.3 Luminal breast cancer 
ER and/or PR positive phenotypes are immunohistochemical surrogates of the 
luminal molecular signature. Luminal type breast cancers are the most prevalent 
subtype and bear variable clinical outcomes and responses to endocrine therapy 
20 
 
and chemotherapy. Further subclassification has divided this group into luminal 
A and luminal B, the first group having more favourable prognosis and greater 
hormone-sensitivity than the latter (2). Expression of the proliferation gene Ki-67 
is helpful in discerning phenotypically these two groups; luminal A have a low Ki-
67 score and luminal B a high Ki-67 score (72). Luminal B group also includes 
the ER/PR positive Her-2 enriched phenotype. 
 
1.3.3.1 Targeted treatments for luminal-type breast cancer 
commonly used in clinical practice. 
(i) Selective Estrogen Receptor Modulators (SERMs) 
SERM’s (tamoxifen, toremifene, raloxifene) bind to estrogen receptors, 
preventing estrogens from binding. In some tissues (i.e. breast) SERMs act as 
estrogen antagonists, in other tissues (i.e. uterus, bones) they act as estrogen 
agonists. Tamoxifen has been used for more than 30 years for the treatment of 
advanced and early hormone-receptor positive breast cancer (73). 
(ii) Aromatase Inhibitors (AIs) 
AIs block the activity of the enzyme aromatase which is responsible for the 
peripheral conversion of androgens to estrogens. AIs only have activity in 
postmenopausal women without ovarian estrogen production. These drugs have 
shown significant activity in the treatment of both advanced and early hormone-
receptor positive breast cancer (74). 
(i) Selective Estrogen Receptor Downregulator (SERD) 
SERD fulvestrant is an antiestrogen. It irreversibly binds to the estrogen receptor 
and acts as an antagonist. Additionally, it prevents dimerisation and causes 
downregulation and destruction of the estrogen receptor. In the clinic it has been 
licenced for the treatment of hormone receptor positive advanced breast cancer 
after failure of other antiestrogen treatment in postmenopausal women (75).  
(ii) Lutenizing Hormone Releasing Hormone (LHRH) analogs or antagonists 
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LHRH analogs (leuprolid, goserelin, triptorelin) ablate ovarian and consequently 
estrogen production in premenopausal women. These drugs are modelled after 
human hypothalamic gonadotropin-releasing hormone and are designed to 
interact with the GnRH receptor and modify the release of FSH and LH 
gonadotrophins by the pituitary gland. After an initial “flare” of FSH and LH 
secretion, gonadotrophin receptor is downregulated and FSH and LH levels 
drop. The absence of gonadotrophins cause a reversible ovarian ablation. LHRH 
analogues are indicated for the treatment of premenopausal hormone receptor 
positive early and advanced breast cancer (76). LHRH antagonists have also 
been developed in order to avoid the initial “flare phenomenon” and soon will be 
approved by regulatory authorities for clinical use in breast cancer.  
1.4 Resistance to currently used targeted therapies 
 
Both HER-2-targeting and endocrine manipulation treatment have improved 
considerably the outcomes of HER-2 positive and hormone receptor positive 
breast cancer respectively. Unfortunately, many patients present primary 
resistance or develop secondary resistance to targeting treatments. Resistance 
is complex because of the numerous downstream molecular signalling pathways 
along with their ability to cross talk. In the case of HER-2 positive breast cancer, 
pathways that have been implicated with resistance to trastuzumab and lapatinib 
include the PI3K-AKT-mTOR, the EGFR, the IGF-IR and other pathways (46).In 
hormone receptor-positive breast cancer the EGFR/HER-2, VEGFR, PI3K-AKT-
mTOR pathways as well as epigenetic changes have been proposed as 
possible resistance mechanisms (37).Since targeted therapies may become 
inactive due to development of resistance through cross-talking escape 
pathways, combining targeted agents might be a strategy to prevent resistance. 
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1.5 Study Objectives 
 
Both Her-2 positive (amplified or overexpressed) and triple negative breast 
cancer, in particular, are associated with poor prognosis (19) (2). The 
development of Her-2 targeted therapies, specifically trastuzumab and lapatinib, 
has improved the prognosis for patients with Her-2 positive breast cancer. 
However, not all Her-2 positive tumours respond to treatment with Her-2 
antagonists, and acquired resistance frequently develops in patients who initially 
respond (77). Triple negative cancers are also resistant to hormone and Her-2 
targeting therapies. 
This project focussed on examining ways to improve response in Her-2 
overexpressing breast cancer and on developing effective targeting therapeutic 
strategies for basal-like breast cancer. 
It is increasingly recognised that molecularly targeted therapies are unlikely to 
be effective as single agents and must be evaluated in combination with other 
agents. As previously reported (78), strategies for optimising the use of novel 
targeted therapies should include: 1. Systematic pre-clinical assessment of 
targeted agents and combinations . 2. Correlative studies in both preclinical and 
clinical settings. 3. Development of reliable biomarkers for patient selection 
and/or measuring response. 
In this project we : 
 tested a number of multi-target kinase inhibitors in Her-2 positive and 
triple negative breast cancer cell lines 
 We tested the most active multi-target kinase inhibitors in combination 
with other agents (targeted therapies and chemotherapy).  
 We identified markers of response to specific multi-target kinase 
inhibitors.  
 Novel pathway inhibitors were also tested in triple negative breast cancer 
cell lines in an attempt to identify potential therapeutic targets.  
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 We assessed the direct anti-tumour effects of a number of these multi-
target kinase inhibitors, including imatinib, sunitinib, pazopanib and 
dasatinib (79).  
 
 Previous studies have shown that triple negative breast cancer cells are 
more sensitive to dasatinib than luminal or Her-2 positive breast cancer 
cell lines (33). We compared sensitivity to dasatinib with sensitivity to 
other multi-target kinase inhibitors and investigated the specific targets 
responsible for sensitivity to dasatinib in triple negative breast cancer 
cells. 
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Chapter 2. Materials and Methods 
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2.1 Cell lines, cell culture and reagents 
Five triple negative breast cancer cell lines (BT20, HCC1937, MDA-MB-231, 
MDA-MB-468, HCC-1143) and four Her2 amplified cell lines (BT474, SKBR3, 
HCC-1419, JIMT-1) were obtained from the American Tissue Culture Collection, 
Manassas, VA. Cell lines were maintained in RPMI-1640 with 10% fetal bovine 
serum (BioWhittaker, Walkersville,MD), at 37ºC with 5% CO2. HCC1937 
medium was also supplemented with 1% sodium pyruvate (Sigma-Aldrich, 
Wicklow, Ireland). JIMT-1 cells were maintained in DMEM with 10% fetal bovine 
serum. Cell cultures were maintained and handled in aseptic conditions. Cell 
lines were subcultured twice a week at a ratio of 1:2 to 1:10 dependent on the 
cell line and on the confluency. Cell culture media was aspirated and the flask 
washed twice with 15ml phosphor buffered saline (PBS). Cells were then 
detached using 1ml trypsin-EDTA solution. Trypsin was neutralized using 20 ml 
of pre-warmed media. All cells were routinely tested for the presence of 
mycoplasma. In case of contamination, cell lines were destroyed and 
experiment repeated. The characteristics of the panel of cell lines tested are 
listed in table 2.1. 
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Table 2.1.Cell lines and characteristics (80). 
Cell lineSub-type  Characteristics 
HCC-1419  
Her-2 (+) 
IDC, EGFR+, ER-, PR-, p53- 
SKBR-3  IDC, Luminal, ER-, PR-, EGFR+, p53+ 
JIMT-1  Basal, ER-, PR-, EGFR+, CK5/6+ 
BT-474  IDC, Luminal, ER+,PR+,EGFR +,CK 5/6-
,p53+ 
HCC-1954 IDC, ER-, EGFR+, CK 5/6- 
BT-20  
3ple (-)  
IDC, Basal, EGFR+, CK 5/6 - ,p53++ 
MDA-MB-231  IDC, Mesenchymal, EGFR+, CK 5/6-, p53++ 
MDA-MB-468 Adenocarcinoma, EGFR+, p53+, PTEN loss 
HCC-1143 Basal, p53+++ 
HCC-1937  IDC, Basal, EGFR+,CK 5/6 + ,p53-, BRCA1mut 
MCF-7 
Luminal IDC, ER+, PR+, C-erbB2 normal 
CAMA-1 
 
Docetaxel (Sanofi-Aventis) and cisplatin (Bristol Myers Squibb) were purchased 
from the Pharmacy Department, St Vincent’s University Hospital, Dublin. 
Dasatinib, imatinib mesylate, sunitinib malate (Sequoia Research Products, 
Pangbourne, UK), pazopanib (GSK), U0126 (Promega), LY294002 
(Calbiochem),5’-deoxy-5’-fluoruridine (5’-DFUR) and rapamycin(Sigma-Aldrich) 
were prepared as 10 mM stocks in DMSO and stored at -20ºC. The inhibitors 
tested and their corresponding targets are listed in table 2.2.  
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Table 2.2. Target specificities of the multi-target kinase inhibitors included in this 
study. Typical IC50 values needed to inhibit signalling through the corresponding 
targets. 
Inhibitor Targets IC 50 (nM) 
Imatinib 
(GlivecTM) 
Bcr-Abl, PDGFR, c-Kit 100-600 (81) 
Sunitinib 
(SutentTM) 
VEGFR-1,-2,-3, PDGFR-a,-b, c-Kit, FLT3, 
CSF-1R, RET 
2-80 (82) 
Pazopanib 
(Votrient™) 
VEGFR-1,-2,-3, PDGFR-a,-b, c-Kit 10-84 (83) 
Dasatinib 
(SprycelTM) 
Abl, PDGFR, c-Kit, Src, EphA receptors 0.6-0.8 (84) 
Rapamycin mTOR <50 (85) 
U0126 MAPK 58-72 (86) 
LY294002 PI3K 1000-50000 
(87) 
 
 
2.2 Proliferation assays 
Proliferation was measured using an acid phosphatase assay. Ninety six-well 
plates were seeded with 3-5 x 103 cells per well. Following overnight incubation, 
drug was added at the appropriate concentrations and incubated for 5 days. 
Medium was removed and cells washed once with phosphate buffered saline 
(PBS). One hundred µl of acid phosphatase substrate [7.25 mM p-nitrophenyl-
phosphate (Sigma) in sodium acetate buffer, pH 5.5] was added to each well 
and incubated at 37ºC for 1 h. Fifty µl of 1 M NaOH was added to stop the 
reaction and the absorbance was read at 405 nM with 620 nM, as the reference 
wavelength (88). 
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2.3 Combination assays and synergy analysis 
The most active targeting agents were tested in combination with active 
chemotherapy in vitro. Fixed ratio combination assays were used in proliferation 
assays as described above and synergy analysis was performed as described in 
section G (statistical considerations). 
2.4 Preparation of cell lysates 
After 6-hours of dasatinib treatment, cells were washed with ice-cold PBS and 
lysed in 500 µl RIPA buffer containing protease inhibitors, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1 mM sodium orthovanadate (Sigma). 
After 20-min incubation on ice, the lysate was passed through a 21-gauge 
needle and centrifuged at 16 000 x g for 5 min at 4ºC. Supernatants were 
collected and stored at -80ºC. Protein quantification was carried out using the 
bicinchoninic acid assay (Pierce Biotechnology). 
2.5 Immunoblotting analysis 
20-50 micrograms of protein in sample buffer was heated to 95ºC for 5 min, 
separated using 7.5% or 10% polyacrylamide gels (Lonza, Basel, Switzerland) 
and transferred to Hybond ECL nitrocellulose membrane (Amersham 
Biosciences, Buckinghamshire, UK). Membranes were blocked with 5% non-fat 
milk powder in phosphate-buffered saline (PBS)–0.1% Tween, at room 
temperature for 1 h. After overnight incubation at 4ºC with primary antibody in 
5% blocking solution, three washes with 0.5% PBS–Tween were performed, 
followed by incubation at room temperature with secondary antibody in 5% 
blocking solution for 1 h. Following three washes with 0.5% PBS–Tween and 
one PBS wash, protein bands were detected using Luminol (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA). Antibodies used were mouse anti-alpha-
tubulin (Sigma), mouse anti-EphA2 (Millipore), mouse anti-Src kinase (Upstate 
Cell Signaling Solutions), rabbit anti-phospho-Srcpy 419 (Biosource Europe), 
caveolin-1 (Millipore)and caveolin-2 (BD Biosciences) (Table 2.3). 
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Table 2.3. Antibodies and corresponding concentrations used for 
immunoblotting analysis. 
Primary antibody Source Concentration (dilution)  
α-tubulin Mouse 1 µg/ml (1:1000)  
EphA2 Mouse 1 µg/ml (1:1000)  
Src 
(pp60srcKinase) 
Mouse 1 µg/ml (1:1000)  
P-Src [pY418] Rabbit 2 µg/ml (1:500)  
Caveolin-1 Rabbit 1 µg/ml (1:1000)  
Caveolin-2 Rabbit 2 µg/ml (1:500)  
. 
2.6 In vivo testing 
In vivo testing was carried out in collaboration with Dr Annette Byrne, Royal 
College of Surgeons in Ireland. All animal experiments were licensed by the 
Department of Health and Children, Ireland and specific ethical protocols 
reviewed by the Animal Research Sub Committee (ARSC) at University College 
Dublin. All studies were in full compliance with EU guidelines.   
For the toxicology study 8 groups of Balb-C mice (Harlan) (3 mice/group) were 
treated with fixed dose of dasatinib (15 mg/kg, by oral gavage,(po) 5 days/week) 
combined with escalating doses of cisplatin (1 mg/kg, 2 mg/kg, 3 mg/kg and 4 
mg/kg, injected intraperitoneally (ip), once a week).  
For the efficacy study, MDA-MB-231 cells (approximately 1x106) were injected 
directly into the mammary fat pad of six-week-old female athymicBalb/C nude 
mice (Harlan). On day 13, 8 mice per group were randomly assigned to 
treatment with: (i) vehicle (50% propylene glycol) (group 1), (ii) dasatinib (15 
mg/kg, po, 5 days/week)(group 2), (iii) cisplatin (4mg/kg, ip, once a week)(group 
3), (iv) dasatinib and cisplatin (group 4) and (v) no treatment (group 5). Tumour 
diameter was serially measured with callipers, and tumour volumes calculated 
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using the formula: volume = width/2 x length/2. Treatment was continued for 
approximately 3 weeks.  
 
2.7 Statistical considerations 
IC50 values were calculated using CalcuSyn software (Biosoft, Cambridge, UK). 
For fixed ratio combination assays, combination indices (CIs) at the ED50 
(effective dose of combination that inhibits 50% of growth) were determined 
using the Chou and Talalay equation (89), on CalcuSyn software (Biosoft, 
Cambridge, UK). CI < 0.9 implies synergy, CI 0.9-1.1 implies additivity and CI > 
1.1 implies antagonism (Table 2.4) (90).  
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Table 2.4. Range of combinations index values which determine synergism or 
antagonism in drug combination studies analysed with the Combination Index 
Method. 
Range of Combination Index (CI) Symbol Description 
< 0.10 + + + + + Very strong synergism 
0.10 – 0.30 + + + + Strong synergism 
0.30 – 0.70 + + + Synergism 
0.70 – 0.85 + + Moderate synergism 
0.85 – 0.90 + Slight synergism 
0.90 – 1.10 ± Nearly additive 
1.10 – 1.20 – Slight antagonism 
1.20 – 1.45 – – Moderate antagonism 
1.45 – 3.30 – – – Antagonism 
3.30 – 10.00 – – – – Strong antagonism 
> 10.00 – – – – – Very strong antagonism 
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Chapter 3. Evaluation of multi-target kinase inhibitors in breast 
cancer cell lines 
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3.1 Introduction 
Our aim was to screen a panel of multi-targeting kinases against a panel of 
breast cancer cell lines, including all subtypes. We focused on Her-2 amplified 
and triple negative cell lines in order to isolate the most active agent to select for 
combination testing. Additionally, in the search for new targets for triple negative 
breast cancer we tested inhibitors of the key signalling pathways, PI3-
K/AKT/mTOR and MAPK. 
The panel of cell lines tested included five Her-2 amplified, 5 triple negative and 
2 ER/PR positive cell lines (table 2.1). 
3.2 Sensitivity to multi-target kinase inhibitors 
Imatinib mesylate (Glivec™) is a small molecule inhibitor of Bcr-Abl, PDGFR 
and c-kit. It is licensed for the treatment of chronic myeloid leukemia and 
gastrointestinal stromal tumours. Typical IC50 values range between 100-600nM 
(81).The cell lines tested showed little sensitivity to imatinib with IC50values over 
3 µΜ (91)(Table 3.1). 
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Table 3.1.Sensitivity to multi-target kinase inhibitors. 
Cell Line  
IC50 values + SD (µM) 
Imatinib Sunitinib Pazopanib Dasatinib 
HCC-1419  
HER-2  
32.3+3.7 8.4+2.9 13.9+4.0 4.7±0.7 
SKBR-3  14.9+2.3 5.4+0.9 18.2+2.2 2.1±0.5 
JIMT-1  23.4+4.1 7.3+1.9 11.2+1.3 0.1±0.01 
BT-474  17.7+3.6 5.0+1.3 11.6+1.1 5.8±0.8 
BT-20  
3ple (-)  
32.5+3.6 9.3+2.5 12.5+1.0 2.5±0.6 
MDA-MB-231  23.6+2.0 6.7+1.4 9.6+4.1 0.04±0.01 
HCC-1937  27.3+2.0 9.1+1.8 13.0+1.8 0.13±0.07 
HCC-1143 NDa ND ND 0.12±0.02 
MDA-MB-468 ND ND ND >5b 
MCF-7  
Luminal 
24.5±3.2 15.5±0.3 7.7±0.4 ND 
CAMA-1  10.5±3.4 20.2±3.0 9.2±0.9 ND 
aND= not determined, bAn IC50 value was not determined as up to 5 µM dasatinib did not 
achieve 50% inhibition of growth. 
 
Pazopanib (Votrient™) is a novel tyrosine kinase inhibitor of VEGFR-1, -2, -3, 
PDGFR-a, -b, and c-kit. It was recently licensed for the treatment of renal cell 
carcinoma and is being tested on clinical trials for breast and other forms of 
cancer. Typical IC50 values range between 10-84nM (83). All cell lines tested 
were resistant to pazopanib with IC50 values greater than 7 µΜ (Table 3.1).  
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 In addition to the targets of pazopanib, sunitinib (Sutent™) also inhibits FLT3, 
CSF-1R and RET. It is currently licensed for the treatment of renal cell 
carcinoma and gastrointestinal stromal tumours. It was also tested in clinical 
trials for unselected patients with breast cancer, with no success. Typical IC50 
values range between 2-80nM (82).Although the IC50 values found were in the 
µM range, the Her2 positive and triple negative cell lines showed greater 
sensitivity to sunitinib than the two luminal cell lines, and the IC50 values were 
consistently lower than for either imatinib or pazopanib in these cell lines (Table 
3.1).   
Dasatinib (Sprycel™) is a novel multi-target inhibitor of Abl, PDGFR, c-Kit, Src, 
EphA receptors (30). It is currently licensed for the treatment of imatinib-
resistant chronic myeloid leukemia and is being tested in clinical trials for breast, 
prostate and other solid tumours. Typical IC50 values range between 0.6-0.8nM 
(91). Among the Her-2 positive cell lines, JIMT-1 showed marked sensitivity to 
dasatinib (Table 3.1). Three of the 5 triple negative cell lines (MDA-MB-231, 
HCC1937 and HCC1143) showed marked sensitivity to dasatinib (Table 3.1). 
BT20 cells were also significantly more sensitive to dasatinib than the other 
multi-target kinase inhibitors. The MDA-MB-468 cells showed resistance to 
dasatinib as only 34.8±6.7% of cell growth was inhibited at concentration of 
800nM of dasatinib. The two non-overlapping targets between dasatinib and the 
other multi-target kinase inhibitors (imatinib, sunitinib, pazopanib), Src and 
EphA2, may contribute to the observed sensitivity to dasatinib. 
Sensitivity to the Src kinase selective inhibitor (Src IC50= 100 nM), PP2, was 
also assessed in the triple negative cell lines but none of the cell lines showed 
sensitivity to PP2 at concentrations up to 5 µM. 
 
3.3 Cell signalling inhibitors in triple negative breast cancer cell lines 
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Rapamycin (Sirolimus) is an antibiotic product of Streptomyces hygroscopicus. It 
binds to the cytosolic protein FK-binding protein 12 (FKBP12). The sirolimus-
FKBP12 complex inhibits the mammalian target of rapamycin (mTOR) pathway 
by directly binding the mTOR Complex1 (mTORC1).  Rapamycin inhibits mTOR 
signaling with ΙC50<50 nM (85). Additionally, it has been shown to directly inhibit 
mTOR kinase activity with IC50 values of 1.74 µM independently of FKBP12, 
implying direct antitumour activity and profound translational repression at the 
high yet clinically relevant concentrations (92).  Three of the 4 triple negative 
breast cancer cell lines showed marked sensitivity to rapamycin with IC50 values 
in the low nanomolar range (30-35 nM) (Table 5). However, the mesenchymal 
MDA-MB-231 cells were resistant to clinically relevant concentrations (Table 
3.2).  
 
Table 3.2.Sensitivity of triple negative cell lines to novel inhibitors. 
Cell lines  
IC50 values ± SD 
 
Rapamycin U0126 LY294002 
HCC-1143 32.4 ± 8.5 nM 14.0 ± 2.3µM 9.3 ± 1.8µM 
HCC-1937 30.4 ± 1.0 nM 18.2 ± 2.0µM 10.4 ± 2.0µM 
MDA-MB-468 35.2±4.7nM 6.3± 0.2µM 8.2 ± 1.4µM 
MDA-MB-231 >2.0 µMa 14.2 ± 3.2µM 10.7 ± 1.8µM 
aAn IC50 value was not determined as up to 2 µM rapamycin did not achieve 50% inhibition of 
growth. 
 
LY 294002 [2-(4-Morpholinyl)-8-phenyl-4 H-1-benzopyran-4-one] is a potent and 
specific cell-permeable inhibitor of PI 3-kinases with IC50 values in the 1–50 µM 
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range (87). LY 294002 competitively inhibits ATP binding to the catalytic subunit 
of PI 3-kinases (93). The 4 triple negative cell lines treated with this inhibitor 
showed some sensitivity to LY 294002 with IC50 values ranging from 8-11 µM 
(Table 3.2). 
Inhibition of MEK1/2 is an attractive strategy for therapeutic intervention in 
cancer because it has the potential to block inappropriate signal transduction, 
regardless of the upstream position of any oncogenic aberration and additionally 
ERK 1/2 are the only known substrates for MEK1/2 phosphorylation and 
signaling. The MEK Inhibitor, U0126, is a potent, cell-permeable inhibitor of 
MAPK (ERK 1/2) activation by inhibiting the kinase activity of MAP Kinase 
Kinase (MAPKK or MEK 1/2). U0126 inhibits MEK1 with an IC50 of 72 nM and 
MEK 2 with an IC50 of 58 nM (86) (94). The IC50 values obtained in the triple 
negative cell lines tested were within the µΜ range suggesting that these cell 
lines are resistant to MEK 1/2 inhibition in vitro (Table 3.2). 
 
3.4 Summary 
Among the targeted therapies tested, sunitinib malate was moderately active in 
the Her-2 amplified cell lines and the triple negative cell lines, and dasatinib 
showed marked activity in most of the triple negative cell lines (Table 3.1). 
The panel of triple negative cell lines were tested with single-agent PI3K 
inhibitor, mTOR inhibitor and MEK1/2 inhibitor. Marked in vitro sensitivity was 
observed with inhibition of mTOR but not the MAPK pathway. Based on our in 
vitro evaluation of a range of inhibitors, dasatinib and rapamycin warrant further 
investigation in triple negative breast cancer, and sunitinib may have some 
activity in HER2 positive and triple negative breast cancer. Based on the non-
overlapping targets of the multi-target kinase inhibitors tested the dasatinib 
sensitivity in the triple negative cell lines may be due to targeting SRC and EphA 
receptors. 
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Chapter 4. Preclinical evaluation of dasatinib in triple negative 
breast cancer cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results in part published in:Tryfonopoulos D, Walsh S, Collins DM, Flanagan 
L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown 
J, Duffy MJ. Src: a potential target for the treatment of triple-negative breast 
cancer. Ann Oncol. 2011 Oct;22(10):2234-40.  
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4.1 Introduction 
Dasatinib showed promising activity in the triple negative breast cancer cell 
lines. Two previous studies have also shown that dasatinib is selectively active 
in triple negative/basal like breast cancer cells (33) (95). Based on the anti-
proliferative effects of dasatinib in the triple negative cell lines, we chose to 
further evaluate the effects of dasatinib in combination with chemotherapy drugs 
in triple negative breast cancer cells in vitro and in vivo. We also investigated 
potential predictive markers of response to dasatinib. 
 
4.2 In vitro evaluation of dasatinib in combination with chemotherapy 
4.2.1 Dasatinib + cisplatin 
The three dasatinib-sensitive triple negative breast cancer cell lines (MDA-MB-
231, HCC-1143, HCC1937) and one dasatinib resistant cell line (MDA-MB-468) 
were treated with fixed-ratio combinations of dasatinib with cisplatin (Figure 4.1). 
Combined treatment with dasatinib and cisplatin was synergistic in the three 
dasatinib sensitive cell lines (CI<0.9) (Table 4.1). In the dasatinib resistant cell 
line MDA-MB-468, the combination of dasatinib with cisplatin had no additive 
effect. CI values were not calculated for MDA-MB-468, as dasatinib did not 
achieve greater than 50% inhibition at the concentrations tested. 
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Figure 4.1.In vitro testing of dasatinib and cisplatin alone and in combination, in 
triple negative breast cancer cell lines. The dasatinib concentration (nM) is 
represented as a ratio of the cisplatin concentration, as indicated. Error bars 
represent the standard deviation of triplicate experiments. 
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Table 4.1. Combination index (CI) values determined for in vitro combinations of 
dasatinib with chemotherapy in triple negative breast cancer cell lines. 
Cell line CI at ED50 ± SD 
 Docetaxel + 
Dasatinib 
5’-DFUR + 
Dasatinib 
Cisplatin + 
Dasatinib 
MDA-MB-231 0.77 ± 0.41 0.66 ± 0.19 0.79 ± 0.11 
HCC-1937 0.83 ± 0.10 0.98 ± 0.40 0.57 ± 0.07 
HCC-1143 1.45 ± 0.42 0.47 ± 0.04 0.74 ± 0.13 
  
 
4.2.2 Dasatinib + 5’-DFUR 
In MDA-MB-231 and HCC-1143 cells, combined treatment with dasatinib and 5’-
5’-DFUR displayed synergy (CI<0.9), whereas the combination was additive in 
HCC-1937 cells (CI=0.98) (Figure 4.2, Table 4.1).  In the dasatinib resistant cell 
line MDA-MB-468, the combination of dasatinib with 5’-5’-DFUR displayed a 
positive interaction.  CI values were not calculated for MDA-MB-468, as 
dasatinib did not achieve greater than 50% inhibition at the concentrations 
tested. 
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Figure 4.2.In vitro testing of dasatinib and 5’-DFUR alone and in combination in 
triple negative breast cancer cell lines. The dasatinib concentration (nM) is 
represented as a ratio of the 5’DFUR concentration, as indicated. Error bars 
represent the standard deviation of triplicate experiments. 
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4.2.3 Dasatinib + docetaxel 
Dasatinib in combination with docetaxel displayed moderate synergy in MDA-
MB-231 and HCC-1937 cells (CI<0.9), but was antagonistic in HCC-1143 cells 
(CI>1.1) (Figure 4.3, Table 4.1). In the dasatinib resistant cell line MDA-MB-468, 
the combination of dasatinib with docetaxel displayed a positive interaction. CI 
values were not calculated for MDA-MB-468, as dasatinib did not achieve 
greater than 50% inhibition at the concentrations tested. 
  
  
Figure 4.3.In vitro testing of dasatinib and docetaxel alone and in combination in 
triple negative breast cancer cell lines. T
represented as a ratio of the docetaxel concentration, as indicated. Error bars 
represent the standard deviation of triplicate experiments.
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4.3 Biomarkers of dasatinib response 
The levels of Src, phosphorylated Src and EphA2, which are targets of 
dasatinib, were analysed in a panel of triple negative and HER2 amplified breast 
cancer cell lines (Figure 4.4A). No difference was observed in the level of Src or 
phosphorylated Src in dasatinib sensitive and resistant cells. However, EphA2 
levels were significantly higher in the dasatinib-sensitive cell lines than in the 
resistant cells (p = 0.0385). 
As other investigators (33) (95) found that expression of caveolin 1 and caveolin 
2 were associated with response to dasatinib, we examined caveolin 1 and 2 
protein levels in our panel of cell lines. Expression of both caveolin 1 and 2 
proteins were also significantly higher in dasatinib-sensitive than dasatinib-
resistant breast cancer cell lines (p <0.00002 and <0.0125, respectively) (Figure 
4.4A-B).  
Following 6-hours of treatment with dasatinib, levels of phosphorylated Src were 
significantly reduced in all cell lines, irrespective of sensitivity to dasatinib 
(Figure 4.5). 
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Figure 4.4.(A)Representative immunoblotting for Src, phospho-Src (Y419), 
EphA2, caveolin 1 (CAV-1) and caveolin 2 (CAV-2) in the breast cancer cell 
lines (dasatinib sensitive: 1. MDA-MB-231, 2. HCC1937, 3. HCC1143, 4. JIMT-
1; dasatinib resistant: 5. MDA-MB-468, 6. BT20, 7. SKBR3, 8. BT474, 9. 
HCC1419). (B) Densitometry analysis of triplicate blots for Src, phospho-Src, 
CAV-1, CAV-2 and EphA2 (relative to tubulin) in dasatinib sensitive and 
resistant cell lines. * indicates p<0.05 using the Students T-test.  
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Figure 4.5Immunoblotting for Src and phospho-Src (Y419) in (1) control cells 
and cells treated with (2) 100 nM or (3) 200 nM dasatinib for 6 hours (single 
determination). 
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4.4 In vivo testing of dasatinib plus chemotherapy in triple negative 
breast cancer 
 
Based on previous results, the combination of dasatinib and cisplatin was 
chosen for in vivo study due to stronger synergy. In addition, since anthracycline 
and taxane treatment is commonly used as adjuvant chemotherapy in triple 
negative breast cancer other non-overlapping chemotherapeutics become of 
interest for use in the 1st or subsequent lines of treatment.   
To determine the safe dose of cisplatin to be administered in combination with 
dasatinib, 8 groups of Balb-C mice (3 mice/group) were treated with fixed dose 
of dasatinib (15 mg/kg, po, 5 days/week) combined with escalating doses of 
cisplatin (1 mg/kg, 2 mg/kg, 3 mg/kg and 4 mg/kg, ip, once a week). No 
significant toxicities were observed with the 4 mg/kg dose, thus this dose was 
selected for the efficacy study. 
For the efficacy study, MDA-MB-231 xenografts were treated with: (i) vehicle 
(50% propylene glycol), (ii) dasatinib (15 mg/kg), (iii) cisplatin (4 mg/kg), (iv) 
dasatinib and cisplatin and (v) no treatment. Treatment with cisplatin alone 
reduced tumour growth (Figure 4.6). Treatment with dasatinib alone also 
reduced tumour growth and a greater effect was observed for the combination of 
dasatinib with cisplatin. However, the vehicle alone also had a significant effect 
on tumour growth. Thus it was not possible to determine whether the enhanced 
effect of dasatinib plus cisplatin was due to dasatinib or caused by the vehicle. 
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Figure 4.6 Growth of MDA-MB-231-Luc xenograft tumours in Balb-C nude mice 
following treatment with (i) vehicle (50% propylene glycol)(n=7), (ii) dasatinib (15 
mg/kg)(n=7), (iii) cisplatin (4 mg/kg)(n=8), (iv) dasatinib and cisplatin (n=8) and 
(v) no treatment (n=7) for 19 days. 
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4.5 Summary 
 
Our results presented in chapter 3 suggest that dasatinib sensitivity in triple 
negative cell lines may be due to targeting SRC or EphA receptors. Western blot 
analysis showed no differential expression of SRC or phosphorylated SRC 
between dasatinib sensitive and dasatinib resistant cell lines. On the contrary, 
expression of EphA 2 was higher in the dasatinib-sensitive cell lines, suggesting 
that EphA2 inhibition may contribute to dasatinib sensitivity in the triple negative 
cells.Caveolin-1 and -2 expression were also higher in the dasatinib-sensitive 
cell lines. Finally, levels of phosphorylated SRC were lower following dasatinib 
treatment in all cell lines (dasatinib-sensitive and –resistant), indicating that 
although SRC is a target of dasatinib it is not a valid pharmacodynamic 
biomarker of response in triple negative cells.  
Combined treatment with dasatinib and cisplatin was synergistic in 3 out of 4 
triple negative cell lines. The combination of dasatinib with 5’-DFUR and 
docetaxel was also additive in 3 out of 4 triple negative cell lines. Therefore the 
best chemotherapy partner for dasatinib in triple negative cell lines proved to be 
cisplatin, which was chosen for the in vivo studies. Unfortunately the results of 
the in vivo study were inconclusive due to an unanticipated effect of the vehicle 
alone on tumour growth, even though the vehicle used has been used in 
previously published studies with dasatinib. Thus, the in vivo testing would need 
to be repeated with an alternative vehicle for the dasatinib. 
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Chapter 5. Evaluation of combinations of sunitinib with current 
therapies for HER2 positive and triple negative breast cancer 
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5.1 Introduction 
Based on previous results (See Chapter 3) and on the strong interaction 
between the Her-2 and VEGF pathways, sunitinib malate was the most 
appropriate agent to use in combination with trastuzumab for the Her-2 amplified 
cell lines. For the triple negative cells, was tested in combination with cisplatin.  
 
5.2 Sunitinib plus trastuzumab in HER-2 positive breast cancer cell 
lines 
In vitro, some of the Her-2 positive cell lines (SKBR-3, BT-474) showed 
moderate sensitivity to sunitinib malate (Table 3.1). Sunitinib was tested in fixed 
ratio combinations with trastuzumab in two trastuzumab sensitive cell lines 
(SKBR3 and BT474) and two trastuzumab-resistant cell lines (JIMT-1 and HCC-
1419). Combined treatment with sunitinib and trastuzumab showed a slightly 
improved response compared to either drug alone, in the 2 trastuzumab 
sensitive cell lines (SKBR3 and BT474) (Figures 5.1 and Table 4). No significant 
enhancement was observed in the trastuzumab resistant cell lines (JIMT-1 and 
HCC-1419). 
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Figure 5.1.Fixed ratio combination assays with sunitinib and trastuzumab in four 
Her-2 positive breast cancer cell lines. Error bars represent the standard 
deviation of triplicate experiments. 
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Table 5.1.Combination treatment with sunitinib and trastuzumab in Her-2 
positive cell lines. Triplicate experiment results. 
Cell Line IC50 
(±stddev) % Growth (± stddev) 
Sunitinib (µM) Sunitinib 
(7.5 µΜ) 
Trastuzumab  
(7.5 nΜ) 
Sunitinib (7.5 µΜ) +  
trastuzumab (7.5 nΜ) 
SKBR-3 5.4 ± 0.9 
7.3 ± 1.9 
5.0 ± 1.3 
8.4 ± 2.9 
45.4 ± 5.1 65.2 ± 5.2 33.3 ± 4.3* 
JIMT-1 60.9 ± 11.3 99.5 ± 1.9 50.4 ± 10.9 
BT-474 57.6 ± 6.1 39.6 ± 6.2 20.1 ± 10.1* 
HCC-1419 90.9 ± 16.3 86.1 ± 5.6 74.5 ± 7.3 
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 5.3 Sunitinib and cisplatin in triple negative breast cancer cell lines 
Sunitinib malate showed modest in vitro activity in the triple negative cell lines. 
Since angiogenesis is a possible target in triple negative breast cancer we 
combined sunitinib with cisplatin, an active chemotherapy drug in the triple 
negative cell line which was more sensitive to sunitinib (MDA-MB-231) and in 
the BRCA-1 deficient cell line (HCC-1937) which is more sensitive to platinum 
agents. The combination of these agents was antagonistic in both cell lines with 
combination indexes (CI) over 1.1(Table 5.2 and Figure 5.2).  
 
Table 5.2.Combinations of cisplatin with sunitinib in triple negative cell lines. 
Cell line  
Sunitinib + Cisplatin 
CI at ED50 ± SD 
MDA-MD-231  2.01 ± 0.62 
HCC-1937  1.37 ± 0.9 
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Figure 5.2.Fixed ratio combination assays with cisplatin and sunitinib in triple 
negative cell lines. Error bars represent the standard deviation of triplicate 
experiments. 
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5.4 Summary 
In trastuzumab sensitive Her-2 amplified cell lines, the combination of sunitinib 
malate and trastuzumab was more active than either drug alone. Sunitinib would 
also be expected to have anti-angiogenic effects in vivo, in addition to its direct 
anti-tumour effects. Indeed a preliminary exploratory study of trastuzumab with 
docetaxel and sunitinib showed encouraging anti-tumour activity in the first line 
treatment of advanced HER2 positive breast cancer (96).  
In the two triple negative cell lines, the combination of sunitinib and cisplatin was 
antagonistic. Sunitinib is currently being tested in a number of clinical trials in 
combination with cisplatin-based regimens in other cancer types but our in vitro 
results suggest this would not be a beneficial combination in triple negative 
breast cancer.  
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Chapter 6. Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
6.1 Discussion  
Translational research has provided us with an abundance of molecularly 
targeted agents. Some of these agents have led to clinical benefit, most of them 
though have failed to provide benefit, possibly due to premature clinical use and 
lack of patient selection. This project aimed to systemically assess targeted 
agents and appropriate combinations in Her-2 amplified and triple negative cell 
lines in vitro. Using the most active targeted agent we attempted to identify 
reliable biomarkers for patient selection and response assessment. Finally we 
tested the most active combination in vivo using xenograft nude mice models. 
 
6.2 Her-2 amplified cell lines 
Trastuzumab monotherapy provides long-term responses in a minority of breast 
cancer patients (55). Several studies have reported data on mechanisms of 
trastuzumab resistance and alternative escape pathways (97) (46) (98) (99) 
(100).  In this study we tested a number of multi-target kinase inhibitors to 
determine if combination therapy could improve response to trastuzumab. In 
general, the Her-2 positive cell lines displayed resistance to the inhibitors tested, 
with the exception of the Her-2 amplified cell line JIMT-1 which was sensitive to 
dasatinib. Interestingly, this cell line has been classified as borderline between 
basal and Her-2 amplified as it expresses basal and luminal cytokeratins (101). 
Sunitinib had modest activity, at concentrations higher than biologically 
achievable, as the mean maximum plasma concentration (Cmax) of the 
standard oral once-daily dose of 50 mg/day sunitinib is reported to be 0.18 µM 
(102). However, as trastuzumab resistance has been associated with higher 
levels of VEGFR and sunitinib targets VEGFR-1,-2,-3, trastuzumab was tested 
in combination with sunitinib. The combination treatment increased the 
effectiveness compared to either drug alone. Even the trastuzumab-resistant 
Her-2+ cell lines (JIMT-1, HCC-1419) displayed greater growth inhibition, 
suggesting that the VEGF pathway may play a role in resistance to trastuzumab. 
Other investigators have found similar effects with dual inhibition of VEGF and 
Her-2 in vitro and in vivo (103). Furthermore, this combination may have greater 
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benefit in vivo due to the anti-angiogenic effects of sunitinib, which are not 
assessed using in vitro proliferation assays. However, the emergence of novel, 
potentially more effective targeting agents (T-DM1, pertuzumab, etc) and the 
premature discontinuation of the sunitinib clinical trials in breast cancer reduced 
our interest in further evaluating this combination. 
6.3 Triple negative cell lines 
Previous studies have shown that triple negative breast cancer cell lines are 
more sensitive to dasatinib than luminal or Her-2 positive breast cancer cell lines 
(33). Our results validated this observation, as triple negative cell lines were 
more sensitive compared to Her-2 positive cell lines. Among the triple negative 
cell lines, the MDA-MB-468 and the BT-20 cells were resistant to dasatinib 
treatment. Interestingly both of these cell lines have amplified EGFR. There is 
significant evidence for cross-talk between EGFR and Src signalling, and Src 
has been implicated in resistance to EGFR targeted therapies. However, it is not 
yet known whether increased EGFR signalling can contribute to resistance to 
EGFR inhibition. The mesenchymal MDA-MB-231 cells were the most sensitive, 
followed by the basal BRCA-1 mutated HCC-1937 and the basal HCC-1143. 
These results are consistent with the results obtained by Finn et al (33), who 
also showed that cell lines, including the MDA-MB-231 cells, which have 
undergone an epithelial-to-mesenchymal transition displayed the greatest 
sensitivity to dasatinib. Our laboratory has also shown that dasatinib inhibited 
cellular invasion and migration in the MDA-MB-231 cell line (104). 
We compared sensitivity to dasatinib with sensitivity to other multi-target kinase 
inhibitors and investigated the specific targets that may be responsible for 
sensitivity to dasatinib. The molecular targets of dasatinib are Abl, PDGFR, c-
Kit, Src and EphA receptors (Table 3.1). Abl is a target of imatinib mesylate, 
PDGFR and c-Kit are targets of imatinib, sunitinib and pazopanib, therefore Src 
and EphA receptors are non-overlapping targets which may contribute to the 
observed sensitivity of triple negative cell lines to dasatinib and resistance to the 
other kinase inhibitors. Other investigators, using gene expression profiling have 
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also identified among others EphA2 and Src as targets of dasatinib in triple 
negative breast cancer (95) (33) (30) (105). However, all triple negative cell lines 
tested were resistant to PP2, a laboratory grade selective Src inhibitor. These 
results suggest that targeting EphA receptors contributes to sensitivity to 
dasatinib in triple negative breast cancer cells. Consistent with this hypothesis, 
protein expression analysis in the panel of cell lines showed that dasatinib-
sensitive cell lines had higher levels of expression of EphA2 compared to 
dasatinib-resistant cell lines. EphA2 receptor overexpression has been detected 
in a variety of cancers, including the majority of breast cancers (106) (107). In 
addition, higher levels of EphA2 protein have been detected in triple negative 
breast cancer cell lines as opposed to nontransformed epithelial cells. 
Upregulation of Eph receptor signalling has been implicated in tumour growth, 
invasion, resistance to anoikis and neovascularisation (108). In addition,we 
found elevated caveolin-1 and -2 levels in the dasatinib-sensitive cells. 
Caveolins interact closely with the Src family kinase and have been identified as 
markers of basal breast cancer (109) (110).  
There was no difference in expression of Src and phosphorylated Src between 
dasatinib sensitive and dasatinib resistant cells. Src expression or activation 
thus does not appear to correlate with sensitivity to dasatinib. Other 
investigators have also reported a lack of correlation between 
Src/phosphorylated-Src levels and dasatinib growth inhibitory ability in breast 
and other cancers (95) (105) (111) (112) (113). With few exceptions though 
(hormone receptors, Her-2, etc) measurement of target expression does not 
correlate effectiveness. Even within a panel of Her-2 amplified cell lines, the 
levels of Her2 protein do not predict sensitivity to trastuzumab (98). Thus, these 
findings do not necessarily rule out Src as a target of dasatinib in triple negative 
breast cancer. Src holds part in a complex network of interacting proteins, 
including EGFR, Her-2, PDGFR, VEGF, etc and activation of this pathway is 
very common in cancer (114). In order to rule out Src as an important target of 
dasatinib in triple negative breast cancer it would be necessary to test for 
sensitivity to dasatinib in an Src negative cell line. All of the cell line tested in this 
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study expressed Src kinase to varying degrees. Evaluating the effect of Src 
kinase and/or EphA2 knockdown in triple negative breast cancer cells may also 
help to elucidate the individual importance of these two targets in sensitivity to 
dasatinib. Interestingly, in a collaborative study, we compared Src expression in 
triple-negative and non triple-negative patient tumour samples and showed that 
although both cytoplasmic and membrane Src were expressed in the majority of 
breast cancers, the frequency of expression was significantly higher in triple-
negative than in non triple-negative samples, suggesting that Src is a potential 
target for the treatment of patients with this subtype of breast cancer (104). 
Other groups have reported predictive gene signatures (EphA2, CAV1, CAV2, 
ANXA1, PTRF and IGFBP2) (95) and (CAV1, Moesin(MSN) and yes-associated 
protein (YAP1)) (33).  All these genes are either targets for dasatinib or 
substrates for Src kinases and are particularly expressed in triple-negative and 
basal-type breast cancer cell lines. In our study, in agreement with previous 
reports showing an association between dasatinib sensitivity and high mRNA 
levels for EPHA2, CAV1 and CAV2, we found similar relationships at the protein 
level, supporting those 3 genes as biomarkers of dasatinib response (figure 3 
A,B) (33) (95) (113).  
The activity of dasatinib is being tested in several clinical trials. Preliminary 
results of a phase II study using single-agent dasatinib in locally advanced or 
metastatic triple negative breast cancer patients reported modest results, with a 
response rate of 4.6% and clinical benefit rate of 9.3% (115). We sought the 
most active chemotherapeutic agent to combine with dasatinib in triple negative 
breast cancer cell lines, in order to optimise its efficacy. Docetaxel and 5’-deoxy-
5’-fluoruridine (a prodrug of 5’-fluoruracil and a metabolite of capecitabine) were 
chosen as they are commonly used in 1st-line treatment of metastatic breast 
cancer, whereas cisplatin was also tested due to its emerging activity in triple 
negative breast cancers (116) (13). Based on our data (Table 4.1 and figures 
4.1-4.3) there was synergistic activity with all 3 combinations in most cases, but 
the strongest synergism was observed with the combination of dasatinib and 
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cisplatin in the 3 dasatinib-sensitive cell lines. In solid tumours dasatinib has 
been reported to synergise with capecitabine and doxorubicin in vitro (105) 
(115). A phase I study of dasatinib in combination with capecitabine in 
metastatic breast cancer patients showed encouraging activity (117). Other 
investigators have reported that in colon cancer patients, oxaliplatin activates 
Src through a ROS-dependent mechanism and combination treatment with 
dasatinib is synergistic in a cell-line dependent manner, with the level of Src 
activation correlating with extent of synergy in vitro (118). To our knowledge 
there are no reports of synergistic activity of dasatinib with cisplatin, especially in 
the highly relevant area of triple negative breast cancer. This was the reason 
this combination was chosen for in vivo study. Unfortunately the results of the in 
vivo study were inconclusive due to an unanticipated effect of the vehicle alone 
on tumour growth, even though the vehicle used has been used in previously 
published studies with dasatinib (119) (120). No explanation could be found in 
the relevant literature explaining this unexpected event. Thus, the in vivo testing 
would need to be repeated with an alternative vehicle for dasatinib. 
Finally, testing of a panel of triple negative cell lines with novel cell signalling 
inhibitors of MEK 1/2, m-TOR and PI3-K as single agents showed that mTOR is 
a more attractive treatment target compared to PI3-K and the MAPK pathway, at 
least in vitro. This is not surprising, as loss of PTEN is a common finding in triple 
negative breast cancer thus leading to increased activation of mTOR (121). 
Targeted treatment against mTOR is currently under extensive clinical study in 
triple negative breast cancer. The MAPK pathway is equally important in triple 
negative breast cancer (40) (41). Lack of activity of single agent MEK 1/2 
inhibitor is not unexpected as the MAPK pathway is often coactivated along with 
the PI3K-Akt-mTOR pathway and therefore combination treatment might be 
needed (42). 
6.4 Conclusions 
Triple negative breast cancer is still a highly unmet medical need and therefore 
target selection and preclinical testing are needed to provide rational drug 
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combinations for clinical testing. Based on our in vitro evaluation of a range of 
inhibitors: 
 dasatinib and rapamycin are active and therefore warrant further 
investigation in triple negative breast cancer.  
 protein levels of EPHA2, CAV1 and CAV2 appear to be useful biomarkers 
of dasatinib response.  
 the combination of dasatinib and cisplatin exhibited synergy in inhibiting 
growth of triple negative cell lines.  
 
Future clinical trials combining dasatinib with cisplatin and testing the validity of 
EPHA2, CAV1 and CAV2 as predictive biomarkers may thus be warranted in 
patients with advanced triple negative breast cancer. 
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